Utility of red Amsler grid screening in a rheumatology clinic

Journal of Rheumatology

Volumn 31, Issue 9, 2004, Pages 1754-1755

  Pluenneke, Anne C ^a   Blomquist, Preston H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Amsler grid; Hydroxychloroquine toxicity; Screening test

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EYE TOXICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RED AMSLER GRID SCREENING; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCOTOMA; SCREENING TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL FIELD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SCOTOMA; VISION SCREENING;

EID: 4444343142     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
2. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482-6.
3. Easterbrook M. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol 1999;26:1866-8.
4. Bienfang D, Coblyn JS, Liang MG, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 2000;27:2703-6.
5. Alarcon GS. How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? [letter]. Arthritis Rheum 2002;46:561.
6. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85 Suppl 4A:23-9.
7. Mindel MS, Safir A, Schare PW. Visual field testing with red targets. Arch Ophthalmol 1983;101:927-9.
8. Percival SPB, Meancock I. Chloroquine: ophthalmological safety and clinical assessment in rheumatoid arthritis. BMJ 1968;3:579-84.
9. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997;36:599-601.
10. Fielder A, Graham E, Jones S, Silman A, Tullo A. Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Eye 1998;12:907-9.
11. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:23-31.
12. Marmor M, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
13. Easterbrook M. Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcon [letter]. Arthritis Rheum 2003;48:863-4.
14. Easterbrook M, The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans Ophthal Soc UK 1985;104:204-7.
15. Easterbrook M. Comparison of threshold and standard Amsler grid testing in patients with established antimalarial retinopathy. Can J Ophthalmol 1992;27:240-2.